Trial reportBMC neuroscience2026
Exploring extracellular vesicle surface markers and microRNA regulation following remote ischemic conditioning in patients with stroke; a randomized-controlled pilot study.
Trial report in BMC neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04266639 (Rheo-Erythrocrine Dysfunction as a Biomarker for RIC Treatment in Acute Ischemic Stroke - Pilot, Single-center, Randomized, Patient-assessor Blinded, Sham-controlled Study), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Rheo-Erythrocrine Dysfunction as a Biomarker for RIC Treatment in Acute Ischemic Stroke - Pilot, Single-center, Randomized, Patient-assessor Blinded, Sham-controlled Study
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Remote ischemic conditioning (RIC) has demonstrated neuroprotective effects, yet translating these effects into clinical efficacy has proven challenging. This study aims to uncover the molecular mechanisms underlying RIC’s protective effects, which could potentially identify new therapeutic targets. We conducted the ENOS pilot study, a patient-assessor blinded, Sham-controlled clinical trial, to investigate the molecular changes in patients diagnosed with acute ischemic stroke (AIS). Patients were assigned to undergo either RIC (n = 9), involving five cycles of transient ischemia and reperfusion of the arm, or a Sham treatment (n = 9), using a similar device with less pressure to avoid creating ischemia, within 48 h of symptom onset. We collected plasma samples at three time points: at inclusion (pre-RIC), two hours post-initial RIC, and after seven days, with RIC administered twice daily. Analysis focused on brain biomarkers, specifically extracellular vesicle (EV) surface markers and circulating microRNAs (miRNAs). We identified significant differences in the regulation of CD62 on EVs and five specific miRNAs (miR-374a-5p, miR-20a-5p + miR-20b-5p, miR-19b-3p, miR-24-3p, miR-30d-5p) between the RIC and Sham groups. Notably, miR-374a-5p, known for its neuroprotective properties, was significantly increased in patients treated with RIC (p = 0.015). Furthermore, the changes of several of these miRNAs were correlated with improvements in red blood cell (RBC) deformability and aggregation during shear stress. In addition, we observed significant increases in CD62 on EVs at both the two-hour and 7-day follow-ups in the RIC group. These findings suggest that RIC may induce specific changes in EV surface markers and circulating miRNAs which could serve as future biomarkers for the RIC response. The trial was registered on clinicaltrails.gov (NCT04266639) on February 12, 2020 before trial initation on July 29, 2020.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.